Epidemiology of atopic dermatitis

Хамаганова, И. В.; Новожилова, О. Л.; Vorontsova, I. V.

doi:10.17116/klinderma201716421-25

Cited by 4 publications

(1 citation statement)

References 35 publications

(58 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a result of our search, we proved that different clinical situations (cancer, lupus erythematosus) were accompanied by false-positive tests for syphilis, but we did not find any mention of false-positive test in atopic dermatitis (AD). Meanwhile, the disease is not rare in different countries [85][86][87][88][89][90][91][92]. Now, we present the case.…”

Section: Own Researchmentioning

confidence: 96%

False-Positive Serologic Reactions for Syphilis

Потекаев¹,

Жукова²,

Хамаганова³

2023

Infectious Diseases

View full text Add to dashboard Cite

The epidemiologic situation of syphilitic infection warrants attention to diagnostic methods. Nontreponemal tests (rapid plasma regain, Venereal Disease Research Laboratory) are less reliable, as there are certain situations when false-positive reactions for syphilis antibodies may appear. Variable examinations were performed and proved that it was necessary to assess the titer of antibodies, as well as confirmation of the diagnosis by treponemal tests (fluorescent treponemal antibody, treponema pallidum hemagglutination assay, enzyme immunoassay, Western blot), were obligatory. In recent decades, new methods were elaborated (e.g., BioPlex total screen, tests with β2-GPI-dependent anticardiolipin antibody, the ARCHITECT syphilis treponema pallidum chemiluminescent immunoassay, the Elecsys immunoassay (Roche Diagnostics)). We present the review of publications on syphilis serologic diagnostics and present our own research. We did not find any mention of a false-positive test in atopic dermatitis and present a case of false-positive reactions for syphilis in such patients.

show abstract

Section: Own Researchmentioning

confidence: 96%

False-Positive Serologic Reactions for Syphilis

Потекаев¹,

Жукова²,

Хамаганова³

2023

Infectious Diseases

View full text Add to dashboard Cite

show abstract

Modern aspects of topical therapy of atopic dermatitis in children

Khardikova¹,

Dmitruk²

2019

Klin. dermatol. venerol.

View full text Add to dashboard Cite

Selective inhibition of JAK1 in treatment of atopic dermatitis: Prescription features and experience with upadacitinib

Круглова

Миченко

Lvov

et al. 2022

Medicinskij alfavit

View full text Add to dashboard Cite

Therapy of moderate-to-severe atopic dermatitis (AD) is associated with a number of diffculties due to the propensity of the disease to a chronic relapsing course, the tendency to develop in childhood and young age. However, a new selective JAK1 inhibitor, which suppresses cytokineinduced inﬂammation in the skin, has been added to the arsenal of AD systemic therapy.Objective. To evaluate the effcacy, antipruritic activity, impact on quality of life, levels of anxiety and depression, and safety of upadacitinib treatment of moderate-to-severe AD in adult patients.Material and methods. The inclusion criteria were the presence of moderate-to-severe AD, age over 18 years, signed informed consent of the patient to participate in the study. Effcacy was assessed based on clinical indices. All patients received upadacitinib (RANVEK) 15 mg once daily with or without food, topical corticosteroids (if needed), and emollients.Results. The number of patients with an IGA score of 0 or 1 was 50%. The dynamics of the maximum intensity of pruritus according to NRS during 16 weeks of therapy was 56.4%. The proportion of patients with an improvement in the assessment of the maximum severity of itching according to NRS ≥3 points at week 16 relative to the baseline was 77.8%. The dynamics of the EASI index in percent was 65.3%, and the number of patients who achieved an EASI-50 response at week 16 was 83.3%, EASI-75 was 61.1%. The dynamics of the overall SCORAD index as a percentage of the initial value for 16 weeks was 76.9%. The DLQI decreased by 68.9%. The number of patients with HADS less than 7 points on a scale of both anxiety and depression was 88.9%.Conclusions. Thus, upadacitinib demonstrates high effcacy in terms of the effect on rashes and pruritus, favorably affects the quality of life and psychosomatic characteristics of patients, and has a favorable safety profle in the treatment of moderate and severe AD in adults.

show abstract

Epidemiology of atopic dermatitis

Cited by 4 publications

References 35 publications

False-Positive Serologic Reactions for Syphilis

False-Positive Serologic Reactions for Syphilis

Modern aspects of topical therapy of atopic dermatitis in children

Selective inhibition of JAK1 in treatment of atopic dermatitis: Prescription features and experience with upadacitinib

Contact Info

Product

Resources

About